The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight ...

And Big Pharmas are making bigger moves now too. Last week, Roche announced a deal with Zealand Pharma, a Danish biotech with four obesity peptides in development including a differentiated ...

Zealand Pharma will receive up to $5.3 billion under its obesity drug partnership with Roche. Roche and Zealand Pharma will co-commercialize petrelintide in the U.S. and Europe, sharing profits 50/50.

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...

We also bring on Zealand Pharma CEO Adam Steensberg to talk about his company’s amylin-targeting obesity treatment, the partnership deal it recently signed with Roche, and his thoughts on the ...

Zealand Pharma is on a hiring spree as it bets on the success of its experimental weight-loss treatment that last month saw Swiss healthcare group Roche swoop in to partner on the drug’s ...